As revised by section 1206 of the HCERA, beginning January 1, 2010, provides for an increase in the Medicaid minimum rebate percentage for single source drugs and innovator multiple source drugs from 15.1% to 23.1%. However, for drugs for clotting factors and those drugs approved by the FDA exclusively for pediatric indicators, the rebate increases to 17.1%. Includes a provision such that any total savings that would be achieved by the state due to the above-referenced rebate increase would be recaptured by the federal government (via reduced payments to the state). Also effective January 1, 2010 is an increase in the rebate for other drugs (generic drugs) from 11% to 13%. Provides for the extension of prescription drug discounts to Medicaid managed care enrollees. Beginning March 23, 2010, provides for an additional rebate for new formulations of existing drugs (but not to new formulations of orphan drugs) provided certain conditions are met. Designates the maximum rebate amount with respect to each dosage form and strength of a single source drug or innovator multiple source drug to be 100% of the Average Manufacturer Price (AMP).